GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (NAS:EMBC) » Definitions » Interest Coverage
中文

Embecta (Embecta) Interest Coverage

: 1.64 (As of Dec. 2023)
View and export this data going back to 2022. Start your Free Trial

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Embecta's Operating Income for the three months ended in Dec. 2023 was $46 Mil. Embecta's Interest Expense for the three months ended in Dec. 2023 was $-28 Mil. Embecta's interest coverage for the quarter that ended in Dec. 2023 was 1.64. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Embecta's Interest Coverage or its related term are showing as below:

EMBC' s Interest Coverage Range Over the Past 10 Years
Min: 1.66   Med: No Debt   Max: No Debt
Current: 1.66


EMBC's Interest Coverage is ranked worse than
91.29% of 425 companies
in the Medical Devices & Instruments industry
Industry Median: 19.77 vs EMBC: 1.66

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Embecta Interest Coverage Historical Data

The historical data trend for Embecta's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Embecta Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23
Interest Coverage
No Debt No Debt No Debt 7.98 2.09

Embecta Quarterly Data
Sep19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.47 2.07 1.90 1.03 1.64

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Embecta's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Embecta Interest Coverage Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Embecta's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Embecta's Interest Coverage falls into.



Embecta Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Embecta's Interest Coverage for the fiscal year that ended in Sep. 2023 is calculated as

Here, for the fiscal year that ended in Sep. 2023, Embecta's Interest Expense was $-107 Mil. Its Operating Income was $224 Mil. And its Long-Term Debt & Capital Lease Obligation was $1,625 Mil.

Interest Coverage=-1* Operating Income (A: Sep. 2023 )/Interest Expense (A: Sep. 2023 )
=-1*224/-107
=2.09

Embecta's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Embecta's Interest Expense was $-28 Mil. Its Operating Income was $46 Mil. And its Long-Term Debt & Capital Lease Obligation was $1,624 Mil.

Interest Coverage=-1* Operating Income (Q: Dec. 2023 )/Interest Expense (Q: Dec. 2023 )
=-1*45.5/-27.7
=1.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Embecta  (NAS:EMBC) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Embecta Interest Coverage Related Terms

Thank you for viewing the detailed overview of Embecta's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Embecta (Embecta) Business Description

Traded in Other Exchanges
Address
300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
Executives
David F Melcher director 1650 TYSONS BOULEVARD, SUITE 1700, MCLEAN VA 22102
Devdatt Kurdikar officer: President and CEO ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Jacob Elguicze officer: Chief Financial Officer ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Jeffrey Z Mann officer: SVP, GC, Head Corp. Dev., Secy 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Jean Casner officer: Chief Human Resources Officer 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Ajay Kumar officer: SVP and CHRO C/O EMBECTA CORP., ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Shaun Curtis officer: SVP, Global Manuf./Sup. Chain C/O EMBECTA CORP., ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
David Albritton director ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417-1880
Milton Mayo Morris director 2121 ALLEN PARKWAY, APT 4075, HOUSTON TX 77019
Brian Capone officer: VP, CAO & Corp. Controller 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Carrie L Anderson director 3005 HIGHLAND PARKWAY, SUITE 200, DOWNERS GROVE IL 60515
Claire Pomeroy director BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Christopher R Reidy director ONE ADP BLVD, ROSELAND NJ 07068
Robert J. Hombach director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015

Embecta (Embecta) Headlines

From GuruFocus

embecta to Report Fiscal First Quarter 2023 Financial Results

By GlobeNewswire GlobeNewswire 01-24-2023

embecta Announces Quarterly Cash Dividend

By sperokesalga sperokesalga 05-12-2023

embecta sponsors educational symposium at ATTD 2023

By sperokesalga sperokesalga 02-22-2023

embecta Announces Quarterly Cash Dividend

By Marketwired 08-08-2023

embecta opens new global headquarters in Parsippany, N.J.

By Stock market mentor Stock market mentor 01-25-2023

embecta Announces Quarterly Cash Dividend

By sperokesalga sperokesalga 02-14-2023